Owen B. Wallace - Jan 2, 2024 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role: Chief Scientific Officer
Signature: /s/ Markus Warmuth, Attorney-in-Fact
Stock symbol: GLUE
Transactions as of: Jan 2, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/4/2024, 04:15 PM
Previous filing: Jan 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	GLUE	Common Stock						5.27K	Jan 2, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GLUE	Stock Option (Right to Buy)	Award	$0	+119K		$0.00	119K	Jan 2, 2024	Common Stock	119K	$5.71	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes an aggregate of 5,266 shares previously acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F2	25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.